CLINICAL_TRIALS ClinicalTrials.gov record update

Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent GVHD After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT00975975
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:35:59.048126+00:00
Published At: 2016-02-26T00:00:00+00:00
Record Updated At: 2016-02-26
Results Posted At: 2016-02-26
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Acute Myelogenous Leukemia", "Acute Lymphocytic Leukemia", "Chronic Myelogenous Leukemia", "Chronic Lymphocytic Leukemia", "Myelodysplasia", "Non-Hodgkin\u0027s Lymphoma", "Hodgkin\u0027s Disease", "Multiple Myeloma", "Myelofibrosis", "Anemia, Aplastic", "Hemoglobinuria, Paroxysmal"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2016-02-26"
protocolSection.identificationModule.nctId: "NCT00975975"
protocolSection.identificationModule.officialTitle: "Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent GVHD After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2016-02-26"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.